Last reviewed · How we verify
BMS-986470
At a glance
| Generic name | BMS-986470 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986470 CI brief — competitive landscape report
- BMS-986470 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI